Currently, there are 5.09M common shares owned by the public and among those 4.70M shares have been available to trade.
The company’s stock has a 5-day price change of -4.63% and -77.99% over the past three months. MTNB shares are trading 37.25% year to date (YTD), with the 12-month market performance down to -93.74% lower. It has a 12-month low price of $0.48 and touched a high of $21.50 over the same period. MTNB has an average intraday trading volume of 292.89K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 16.41%, 14.99%, and -87.49% respectively.
Institutional ownership of Matinas Biopharma Holdings Inc (AMEX: MTNB) shares accounts for 10.94% of the company’s 5.09M shares outstanding.
It has a market capitalization of $3.56M and a beta (3y monthly) value of 1.56. The earnings-per-share (ttm) stands at -$4.56. Price movements for the stock have been influenced by the stock’s volatility, which stands at 49.87% over the week and 20.55% over the month.
Analysts forecast that Matinas Biopharma Holdings Inc (MTNB) will achieve an EPS of -0.78 for the current quarter, 0 for the next quarter and -3.0 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.78 while analysts give the company a high EPS estimate of -0.78. Comparatively, EPS for the current quarter was -1.5 a year ago. Earnings per share for the fiscal year are expected to increase by 26.18%, and 63.05% over the next financial year.
SunTrust on their part issued Buy rating on January 23, 2020.
